2017 Report on Advances in Cancer Medicine 1: Statistics, Immunotherapy and Precision Medicine

Message from the president of the American Society of Clinical Oncology, ASCO
“I am pleased to present Clinical Cancer Advances 2017which highlights the most promising advances in patient-oriented cancer research compared with the past. Over the past year there have been promising developments in patient-centered cancer research. The report offers us an opportunity, at an exciting time for cancer research, to reflect on how quickly our understanding of cancer is improving. A year ago, the White House announced the National Cancer Moonshot program to accelerate progress against cancer. This shared vision reinvigorated cancer research communities, identified new areas of scientific collaboration and raised our ambitions for possibilities beyond the progress we are already making.
When I entered this field 35 years ago, I could not imagine where we would be today. We can now detect cancer earlier, target treatments more effectively and manage side effects more effectively so that patients can live better. Today, two out of 3 people diagnosed with cancer live at least 5 years after diagnosis, compared with roughly one in two in the 1970s. This progress has resulted from decades of advances collectively expanding our understanding of the molecular foundations of cancer.
For now, the best example of ASCO’s Advance of the Year for 2017 is:
Immunotherapy 2.0 . Last year brought a new wave of success with immunotherapy. Research demonstrated that this approach could be effective against difficult-to-treat, advanced cancers previously considered untreatable. Researchers are now trying to identify biomarkers that may help increase treatment effectiveness and determine who is likely to benefit from immunotherapy. This knowledge will enable oncologists to make evidence-based decisions so that as many patients as possible can benefit from this new treatment approach. Each successive advance builds on earlier work by generations of cancer researchers.
Importantly , the advances described in this report would not have been possible without volunteers participating in clinical trials as part of their treatment. Much still lies ahead. Many questions remain about how cancer develops and spreads and how it should be treated (basic oncology). As you read Clinical Cancer Advances 2017, I hope you will be inspired, as I am, by the gains made by the clinical cancer research community over the past year and by the promise of a new era of advances on the horizon.
This report presents the most important cancer advances of 2016
Cancer in numbers
The World Health Organization (WHO) estimates that in 2012 there were 14 million new cancer diagnoses; over the next 20 years this will reach 22 million annually. Cancer-related deaths may also increase during the same period because of rising cancer numbers. Of every 10 cancer-related deaths, 7 occur in Africa, Asia, Central and South America, where access to cancer screening and treatment is limited.
In the United States, an estimated 1.7 million people were diagnosed with cancer in 2016. Because of the growing older population, the annual incidence of cancer in the United States is expected by 2030 to reach 2,2 million per year.
The good news is that, for most people, a cancer diagnosis is less frightening than it used to be
Today, %68 of adults and %81 of children with cancer will survive at least 5 years after diagnosis. This is a major improvement compared with only %50 of adults and %62 of children surviving 5 years in the 1970s. Although cancer has been declining over the past 20 years, annual cancer-related deaths in the United States remain high because of total population growth and aging (2017 United States cancer statistics and their implications).
Accelerated by the 1971 National Cancer Act and subsequently by a responsive research infrastructure and an increasingly innovative regulatory environment, cancer medicine now offers new treatment options. Even in the past 1 year, the United States Food and Drug Administration (FDA) has approved many new cancer drugs. Cancer immunotherapy is one example of this accelerating progress.
What lies ahead for cancer immunotherapy?
Its discovery was a hundred years ago; now cancer immunotherapy has become a standard treatment option for many cancer types. In 2016, the FDA approved new-generation immunotherapies for lung, kidney, bladder, and head and neck cancers, as well as Hodgkin lymphoma (HL). For some people with these advanced cancers, the advent of cancer immunotherapy is truly life-changing. It often offers a chance to live longer and better. Many researchers believe this initial wave of success with cancer immunotherapy is only the beginning. To build further on our success, we must remember that fewer than half of patients receiving it actually benefit, and we must find solutions to immunotherapy resistance (immunotherapy resistance).
For some cancers, it is anticipated that a subset of tumors with many genetic mutations may be more responsive to available immunotherapy options. While trying to determine who will benefit, we are also investigating whether combining immunotherapies with each other or with other cancer treatments, such as radiation therapy and chemotherapy, could extend the impact of this new group of treatments. These efforts mark the next phase of immunotherapy: Immunotherapy 2.0: Improving and Using Patient Selection.
Precision medicine
The advances highlighted in this report demonstrate an important trend driving progress against cancer today: cancer treatments are becoming increasingly precise, bringing a more personalized approach to treatment selection. Research into cancer biology is accelerating the rapid development of new treatments targeting key molecules that allow cancers to grow and spread. In 2016 alone, this strategy paved the way for new targeted therapies for patients with cancers such as lung, breast and kidney cancer.
Today, new molecular technologies can rapidly reveal molecular alterations in tumors or identify cancer DNA circulating freely in the blood (liquid biopsy). For a growing number of patients, such alterations can be matched to available targeted therapies or experimental therapies being tested in clinical trials. Although this is not yet a routine approach, early research suggests that it may provide feasible new treatment options for patients with a broad range of otherwise untreatable cancer types.”
In our next article, we will continue the Report on Advances in Cancer Medicine.
Sources
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
J Clin Oncol 35. 2017 by American Society of Clinical Oncology
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.